Patents by Inventor Moses B.I. Goddard

Moses B.I. Goddard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ARPE-19 as a Platform Cell Line for Encapsulated Cell-Based Delivery
    Publication number: 20090269319
    Abstract: ARPE-19 cells were evaluated as a platform cell line for encapsulated and unencapsulated cell-based delivery technology. ARPE-19 cells were found to be hardy (the cell line is viable under stringent conditions, such as in central nervous system or intra-ocular environment); can be genetically modified to secrete the protein of choice; have a long life span; are of human origin; have good in vivo device viability; deliver efficacious quantity of growth factor; trigger no or low level host immune reaction, and are non-tumorigenic.
    Type: Application
    Filed: July 8, 2009
    Publication date: October 29, 2009
    Applicant: NEUROTECH USA, INC.
    Inventors: Weng Tao, David H. Rein, Brenda J. Dean, Paul F. Stabila, Moses B.I. Goddard
  • ARPE-19 as a Platform Cell Line for Encapsulated Cell-Based Delivery
    Publication number: 20090269389
    Abstract: ARPE-19 cells were evaluated as a platform cell line for encapsulated and unencapsulated cell-based delivery technology. ARPE-19 cells were found to be hardy (the cell line is viable under stringent conditions, such as in central nervous system or intra-ocular environment); can be genetically modified to secrete the protein of choice; have a long life span; are of human origin; have good in vivo device viability; deliver efficacious quantity of growth factor; trigger no or low level host immune reaction, and are non-tumorigenic.
    Type: Application
    Filed: July 7, 2009
    Publication date: October 29, 2009
    Applicant: NEUROTECH USA, INC.
    Inventors: Weng Tao, David H. Rein, Brenda J. Dean, Paul F. Stabila, Moses B.I. Goddard
  • ARPE-19 as a platform cell line for encapsulated cell-based delivery
    Patent number: 7115257
    Abstract: ARPE-19 cells were evaluated as a platform cell line for encapsulated and unencapsulated cell-based delivery technology. ARPE-19 cells were found to be hardy (the cell line is viable under stringent conditions, such as in central nervous system or intra-ocular environment); can be genetically modified to secrete the protein of choice; have a long life span; are of human origin; have good in vivo device viability; deliver efficacious quantity of growth factor; trigger no or low level host immune reaction, and are non-tumorigenic.
    Type: Grant
    Filed: April 6, 2000
    Date of Patent: October 3, 2006
    Assignee: Neurotech S.A.
    Inventors: Weng Tao, David H. Rein, Brenda J. Dean, Paul F. Stabila, Moses B. I. Goddard
  • ARPE-19 as a platform cell line for encapsulated cell-based delivery
    Patent number: 6361771
    Abstract: ARPE-19 cells were evaluated as a platform cell line for encapsulated and un-encapsulated cell-based delivery technology. ARPE-19 cells were found to be hardy (the cell line is viable under stringent conditions, such as in central nervous system or intra-ocular environment); can be genetically modified to secrete the protein of choice; has a long life span; is of human origin; has good in vivo device viability; delivers efficacious quantity of growth factor; triggers no or low level host immune reaction, and is non-tumorigenic.
    Type: Grant
    Filed: April 5, 2000
    Date of Patent: March 26, 2002
    Assignee: Neurotech S.A.
    Inventors: Weng Tao, David H. Rein, Brenda J. Dean, Paul F. Stabila, Moses B.I. Goddard